Psilocybin shows potential as promising treatment for major depressive disorder in Phase 2 trial

Psilocybin, a psychedelic compound found in certain mushrooms, has potential as a treatment for Major Depressive Disorder (MDD), according to a phase 2 clinical trial.

Adults with MDD who received a single dose of psilocybin showed a significant and sustained reduction in depressive symptoms and functional disability compared to those who received a placebo.

The treatment was found to be safe when administered with psychological support, although it was associated with a higher rate of adverse events.

Reference
Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;doi: 10.1001/jama.2023.14530. Epub ahead of print. PMID: 37651119.